LOS ANGELES, Feb. 13, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ: NMRA) for violations of the federal securities laws.Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on September 15, 2023, are encouraged to contact the ...

ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against (“Neumora” or the “Company”) (NASDAQ: NMRA) on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to its September 15, 2023 initial public offering (the “IPO”), and who were damaged thereby. The lawsuit alleges that certain documents issued in connection with the IPO were inaccurate and misleading, contained inaccurate and misleading ...

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or tra ...

SAN DIEGO, Feb. 10, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant to the Offering Documents issued in connection with the Company's initial public offering ("IPO") on September 15, 2023.  Neumora is a clinical-stage biopharmaceutical company.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800 ...

NEW YORK, Feb. 9, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"). If you wish to serve as lead plaintiff, you must move the Court no later than A ...

SAN DIEGO, Feb. 7, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant and/or traceable to Neumora's registration statement issued in connection with Neumora's initial public offering (the "IPO") held on September 15, 2023, have until April 7, 2025 to seek appointment as lead plaintiff of the Neumora class action lawsuit. Captioned Chang v. Neumora Therapeutics, Inc., No. 25-cv-01072 ( ...

NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) securities in Neumora’s initial public offering (the “IPO”) held on September 15, 2023 or thereafter and tracable to it, inclusive (the “Class Period”). The law ...

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading information in its IPO documents, which has resulted in significant stock price decline since the IPO [1][4]. Company Overview - Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases [2]. IPO Details - Neumora conducted its initial public offering (IPO) on September 15, 2023, selling 14.7 million shares at a price of $17.00 per share [2]. Allegations in the Lawsuit - The lawsuit claims that the IPO offering documents were materially false and misleading, failing to disclose critical information regarding the Phase Two and Phase Three clinical trials of Neumora's flagship therapeutic candidate, Navacaprant [3]. - Specific allegations include the amendment of trial inclusion criteria to justify the Phase Three program and the lack of adequate data in the Phase Two trials to predict outcomes accurately [3]. Stock Performance - Following the IPO, Neumora's stock price has plummeted from $17.00 per share to $1.91 per share as of February 5, 2025, representing an 88.7% decline [4].

Shares of Neumora Therapeutics (NMRA) lost more than 80% on Thursday after reporting the failure of its lead pipeline drug, navacaprant, in a late-stage study for major depressive disorder (MDD).The phase III KOASTAL-1 study evaluated the efficacy and safety of navacaprant against placebo in adults with moderate-to-severe MDD over a six-week treatment period. The study failed to achieve its primary endpoint – treatment with the drug failed to demonstrate a significant improvement over placebo in alleviating ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...